In December 2020, [68Ga]Ga-PSMA-11, also known as [68Ga]Ga-PSMA-HBED-CC, was the first 68Ga-labeled radiopharmaceutical approved by the United States Food and Drug Administration (USFDA) for the PET imaging of PSMA-positive prostate cancer [52]. Here, FOLH1 is linked to prostate carcinoma.